USD 41.74
(-0.05%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 19.07 Million USD | 124.63% |
2022 | 8.49 Million USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | -100.0% |
2019 | 7.33 Million USD | 743.61% |
2018 | 869 Thousand USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | -100.0% |
2015 | 1.00 USD | 0.0% |
2014 | 1.00 USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 23.93 Million USD | 3.76% |
2024 Q3 | 26.42 Million USD | 10.41% |
2024 Q1 | 23.07 Million USD | 20.94% |
2023 Q3 | 17.27 Million USD | 10.23% |
2023 FY | 19.07 Million USD | 124.63% |
2023 Q4 | 19.07 Million USD | 10.43% |
2023 Q1 | 11.37 Million USD | 33.94% |
2023 Q2 | 15.67 Million USD | 37.78% |
2022 Q3 | 5.17 Million USD | 27.49% |
2022 Q2 | 4.05 Million USD | 63.38% |
2022 Q1 | 2.48 Million USD | 0.0% |
2022 FY | 8.49 Million USD | 0.0% |
2022 Q4 | 8.49 Million USD | 64.06% |
2021 Q2 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2020 Q3 | 11.37 Million USD | 1.25% |
2020 FY | - USD | -100.0% |
2020 Q4 | - USD | -100.0% |
2020 Q1 | 9.77 Million USD | 33.38% |
2020 Q2 | 11.23 Million USD | 14.86% |
2019 Q2 | 4.65 Million USD | 100.13% |
2019 FY | 7.33 Million USD | 743.61% |
2019 Q4 | 7.33 Million USD | 25.34% |
2019 Q3 | 5.84 Million USD | 25.54% |
2019 Q1 | 2.32 Million USD | 167.89% |
2018 Q4 | 869 Thousand USD | 0.7% |
2018 Q1 | - USD | 0.0% |
2018 FY | 869 Thousand USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q3 | 863 Thousand USD | 0.0% |
2017 Q2 | - USD | -100.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q1 | 1.00 USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 Q1 | 1.00 USD | 0.0% |
2016 Q3 | 1.00 USD | 0.0% |
2016 Q2 | 1.00 USD | 0.0% |
2016 Q4 | - USD | -100.0% |
2016 FY | - USD | -100.0% |
2015 Q4 | 1.00 USD | 0.0% |
2015 Q3 | - USD | -100.0% |
2015 Q2 | 1.00 USD | 0.0% |
2015 Q1 | - USD | -100.0% |
2015 FY | 1.00 USD | 0.0% |
2014 Q1 | 1.00 USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | 1.00 USD | 0.0% |
2014 FY | 1.00 USD | 0.0% |
2014 Q2 | - USD | -100.0% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Editas Medicine, Inc. | - USD | -Infinity% |
Dynavax Technologies Corporation | 53.29 Million USD | 64.203% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 75.357% |
Perrigo Company plc | 1.14 Billion USD | 98.328% |
Illumina, Inc. | 587 Million USD | 96.75% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.625% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -83.918% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.771% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Heron Therapeutics, Inc. | 42.11 Million USD | 54.7% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.261% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
Waters Corporation | 516.23 Million USD | 96.305% |
Biogen Inc. | 2.52 Billion USD | 99.245% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -73.45% |
Adicet Bio, Inc. | - USD | -Infinity% |
Cara Therapeutics, Inc. | 2.82 Million USD | -576.214% |
bluebird bio, Inc. | 22.91 Million USD | 16.768% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 70.931% |
FibroGen, Inc. | 41.56 Million USD | 54.106% |
Agilent Technologies, Inc. | 1.03 Billion USD | 98.15% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 78.601% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 68.045% |
Myriad Genetics, Inc. | 20.1 Million USD | 5.095% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 99.256% |
Abeona Therapeutics Inc. | -2.44 Million USD | 880.524% |
Mettler-Toledo International Inc. | 385.86 Million USD | 95.056% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 98.277% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 97.418% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 32.89% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -96.538% |
Verastem, Inc. | - USD | -Infinity% |
Nektar Therapeutics | 16.1 Million USD | -18.477% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -26.039% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 94.092% |
OPKO Health, Inc. | 65.69 Million USD | 70.964% |
Exelixis, Inc. | 17.32 Million USD | -10.119% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 50.193% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -146.779% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 12.02 Million USD | -58.649% |
Imunon, Inc. | - USD | -Infinity% |
Blueprint Medicines Corporation | 21.22 Million USD | 10.116% |
Insmed Incorporated | 83.24 Million USD | 77.085% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 85.05% |
TG Therapeutics, Inc. | 39.82 Million USD | 52.098% |
Incyte Corporation | 62.97 Million USD | 69.707% |
Emergent BioSolutions Inc. | 328.9 Million USD | 94.2% |